MAIA Biotechnology, Inc.

MAIA Biotech is a targeted therapy, immuno-oncology company focused on the development and commercialization of first-in-class drugs. $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

MAIA Biotechnology provided a patient enrollment update for its pivotal Phase 3 THIO-104 trial evaluating ateganosine in advanced #NSCLC.

The company is targeting up to 100 patients by year-end and expects an interim analysis in 2027.

Read more: https://t.co/Yo2P7KhP8t $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

MAIA CEO Vlad Vitoc and Director Stan Smith increased their ownership positions through open market purchases of MAIA common stock.

The continued investments underscore confidence in MAIA's telomere-targeting immuno-oncology platform.

Learn more: https://t.co/Conr1cmzbZ $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

Over the weekend at #ASCO26, MAIA CEO Vlad Vitoc and Dr. Tomasz Jankowski presented the company's THIO-104 Trial in Progress poster.

The level of engagement surrounding MAIA's clinical programs remains encouraging. Learn more about THIO-104: https://t.co/pyLhsbxykw $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at #ASCO2026.

Read more: https://t.co/pyLhsbxykw $MAIA @ASCO

[MAIA Biotechnology, Inc. @MAIABiotech]

MAIA Biotechnology is advancing its NSCLC clinical program across multiple stages, including U.S. expansion and continued long-term survival follow-up in Phase 2.

Read the update from Diamond Equity Research: https://t.co/pimj6gYLtE $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

.@Diamondequities released an updated research note on MAIA Biotechnology highlighting continued progress across the company’s clinical development programs, including the ongoing THIO-101 Phase 2 expansion trial in advanced NSCLC.

Read more: https://t.co/OtYZfV6YU6 $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

@elonmusk Bravo, Elon!

[MAIA Biotechnology, Inc. @MAIABiotech]

Roughly 50,000 NSCLC patients progress to third-line of treatment each year in the U.S., underscoring the need for new therapeutic approaches.

MAIA’s THIO-101 study is evaluating a telomere-targeting investigational therapy in this population. https://t.co/ks0yj7YlzG $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

Phase 2 data from MAIA’s THIO-101 study show measures of efficacy, including disease control, response rates, and survival, above historical standard-of-care benchmarks in heavily pre-treated NSCLC. More: https://t.co/ks0yj7YlzG $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

ICYMI: MAIA Biotechnology has activated its first U.S. clinical site for the Phase 2 THIO-101 expansion study, with additional U.S. sites planned in 2026, marking a key milestone for the company.

Learn more: https://t.co/ks0yj7YlzG $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

Today, MAIA Biotechnology announced expansion of its Phase 2 THIO-101 trial with the activation of its first U.S. clinical site at Summit Medical Group in New Jersey, evaluating ateganosine in third-line NSCLC patients.

Read more: https://t.co/ks0yj7YlzG $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

New interview in @BioTuesdays: MAIA Biotechnology’s CEO Vlad Vitoc, MD, MBA, outlines its telomere-targeting approach and highlights Phase 2 results for ateganosine in NSCLC.

• 17.8 months overall survival
• 88% disease control rate

Read here: https://t.co/73fAGel4C5 $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

MAIA expects recent $33M capital raise to fully support its ongoing Phase 3 trial of its lead investigational therapy ateganosine, as a treatment for #NSCLC.

Read more: https://t.co/FNohXIAztI $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

Coverage from @PharmaNowGlobal highlights MAIA Biotechnology’s ongoing Phase 2 THIO-101 trial in NSCLC. Eight patients treated with ateganosine followed by cemiplimab exceeded 2-year survival after prior checkpoint inhibitor failure.

Learn more: https://t.co/pMjIhGx9b6 $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

MAIA Biotechnology presented updated THIO-101 Phase 2 trial results at #ELCC2026. Eight patients with NSCLC treated with ateganosine + Libtayo surpassed 2-year survival following prior therapies.

Subscribers can read the @NobleCapMkts report here: https://t.co/AQz5aVeODk $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

MAIA Biotechnology shared data from the Phase 2 THIO-101 trial in NSCLC at #ELCC2026. Eight patients treated with ateganosine sequenced with cemiplimab achieved overall survival exceeding 2 years after prior therapies.

Read more from @cure_today: https://t.co/5kx4q9Mrfy $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

MAIA is advancing ateganosine, a potential first-in-class telomere-targeting agent. It is designed to disrupt telomeres in cancer cells and work in sequence with checkpoint inhibitors.

Now in a Phase 3 NSCLC trial, with interim analyses ahead: https://t.co/l37WMOQCxI $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

From #ELCC2026 in Copenhagen: MAIA’s poster presentation highlighted Phase 2 THIO-101 data in #NSCLC showing overall survival beyond two years for eight patients treated with ateganosine sequenced with cemiplimab.

Read more: https://t.co/1enKyQP9IW $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

Ateganosine utilizes a dual mechanism of action with direct telomere-targeting and immune system activation. While we advance our lead candidate in NSCLC, R&D continues on our 2nd-generation pipeline for multiple tumor types. https://t.co/1tA8IUf6p8 $MAIA

[MAIA Biotechnology, Inc. @MAIABiotech]

Ateganosine continues to deliver unprecedented efficacy in third-line NSCLC. Interim Phase 2 data show a median overall survival of 17.8 months - 3x the current chemotherapy standard. Learn more: https://t.co/1tA8IUf6p8 $MAIA